Hartford Financial Management Inc. Has $81,000 Stock Holdings in Fennec Pharmaceuticals Inc (NASDAQ:FENC)

Share on StockTwits

Hartford Financial Management Inc. boosted its position in Fennec Pharmaceuticals Inc (NASDAQ:FENC) by 65.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 20,300 shares of the company’s stock after buying an additional 8,000 shares during the quarter. Hartford Financial Management Inc. owned approximately 0.10% of Fennec Pharmaceuticals worth $81,000 as of its most recent filing with the SEC.

Separately, Geode Capital Management LLC boosted its stake in shares of Fennec Pharmaceuticals by 16.0% during the 4th quarter. Geode Capital Management LLC now owns 39,489 shares of the company’s stock worth $251,000 after acquiring an additional 5,441 shares during the period. 48.39% of the stock is currently owned by institutional investors.

Shares of FENC opened at $4.59 on Wednesday. The firm has a market cap of $90.00 million, a PE ratio of -9.18 and a beta of -0.17. The stock has a 50-day moving average price of $4.17. Fennec Pharmaceuticals Inc has a 12-month low of $3.26 and a 12-month high of $10.55.

Several research analysts have recently commented on FENC shares. Wedbush reiterated an “outperform” rating and set a $16.00 target price on shares of Fennec Pharmaceuticals in a research note on Friday, May 10th. Zacks Investment Research upgraded Fennec Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 30th. Finally, HC Wainwright set a $17.00 target price on Fennec Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, May 28th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $12.50.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

Featured Article: Preferred Stock

Want to see what other hedge funds are holding FENC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fennec Pharmaceuticals Inc (NASDAQ:FENC).

Institutional Ownership by Quarter for Fennec Pharmaceuticals (NASDAQ:FENC)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Okta Inc  CFO William E. Losch Sells 21,108 Shares of Stock
Okta Inc CFO William E. Losch Sells 21,108 Shares of Stock
SmileDirectClub  Major Shareholder Cd&R Investment Associates X, Sells 2,275,857 Shares of Stock
SmileDirectClub Major Shareholder Cd&R Investment Associates X, Sells 2,275,857 Shares of Stock
Okta Inc  Director Michael R. Kourey Sells 17,500 Shares
Okta Inc Director Michael R. Kourey Sells 17,500 Shares
Solaredge Technologies Inc  VP Zvi Lando Sells 28,604 Shares
Solaredge Technologies Inc VP Zvi Lando Sells 28,604 Shares
Aerojet Rocketdyne Holdings Inc  CEO Eileen P. Drake Sells 38,656 Shares of Stock
Aerojet Rocketdyne Holdings Inc CEO Eileen P. Drake Sells 38,656 Shares of Stock
RealPage Inc  CEO Stephen T. Winn Sells 50,000 Shares of Stock
RealPage Inc CEO Stephen T. Winn Sells 50,000 Shares of Stock


© 2006-2019 Ticker Report